Inactive Instrument

Dicerna Pharmaceuticals, Inc.

Equities

DRNA

US2530311081

Biotechnology & Medical Research

Dicerna Presents PHYOX2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021

November 05, 2021 at 10:23 am EDT

LEXINGTON, Mass. - Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, announced results of the PHYOX2 pivotal clinical trial of nedosiran, an investigational GalXC RNAi candidate for the treatment of primary hyperoxaluria (PH), in a late-breaker poster presentation at the American Society of Nephrology (ASN) Kidney Week 2021.

In the PHYOX2 pivotal trial, which included patients with PH type 1 (PH1) and PH type 2 (PH2), nedosiran demonstrated a statistically significant reduction from baseline in urinary oxalate (Uox) excretion compared to placebo (p

Latest news about Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals Coverage Dropped by Chardan After Novo Nordisk Closes Acquisition	21-12-30	MT
Chardan Drops Coverage on Neutral-Rated Dicerna Pharmaceuticals on Acquisition by Novo Nordisk	21-12-30	MT
Dicerna Pharmaceuticals, Inc.(NasdaqGS:DRNA) dropped from S&P Global BMI Index	21-12-30	CI
Dicerna Pharmaceuticals, Inc.(NasdaqGS:DRNA) dropped from S&P TMI Index	21-12-30	CI
Dicerna Pharmaceuticals, Inc.(NasdaqGS:DRNA) dropped from S&P Biotechnology Select Industry Index	21-12-30	CI
Novo Nordisk Completes Dicerna Pharmaceuticals Acquisition	21-12-28	MT
Novo Nordisk Closes on $3.3 Billion Acquisition of Dicerna Pharmaceuticals	21-12-28	MT
Dicerna Pharmaceuticals, Inc.(NasdaqGS:DRNA) dropped from NASDAQ Composite Index	21-12-28	CI
Novo Nordisk A/S (CPSE:NOVO B) completed the acquisition of remaining 97% stake in Dicerna Pharmaceuticals, Inc..	21-12-27	CI
Dicerna Pharmaceuticals, Inc.(NasdaqGS:DRNA) dropped from NASDAQ Biotechnology Index	21-12-17	CI
Chardan Downgrades Dicerna Pharmaceuticals to Neutral Rating From Buy on Proposed Acquisition by Novo Nordisk, Adjusts PT to $38.25 From $28	21-12-09	MT
Chardan Downgrades Dicerna Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $38.25 From $28 on Pending Acquisition	21-12-09	MT
Insider Sell: Dicerna Pharmaceuticals	21-11-22	MT
Stifel Downgrades Dicerna Pharmaceuticals to Hold From Buy, Adjusts Price Target to $38 From $35	21-11-22	MT
Alnylam Pharmaceuticals Upgraded to Outperform From Sector Perform by RBC After R&D Day, Price Target Raised to $225 From $144	21-11-22	MT
North American Morning Briefing : Stock Futures -3-	21-11-22	DJ
B. Riley Downgrades Dicerna Pharmaceuticals to Neutral from Buy After Announcing $3.3 Billion Sale to Novo Nordisk, Lifts PT to $38.25 from $35	21-11-19	MT
RBC Downgrades Dicerna Pharmaceuticals to Sector Perform From Outperform, Lifts PT to $38.25 From $30 on Novo Nordisk Deal; Speculative Risk Qualifier Kept	21-11-19	MT
HC Wainwright Downgrades Dicerna Pharmaceuticals to Neutral From Buy, Adjusts PT to $38.35 From $32	21-11-18	MT
Health Care Stocks Ending Little Changed in Quiet Trading	21-11-18	MT
Health Care Stocks Weakening This Afternoon	21-11-18	MT
Sector Update: Health Care	21-11-18	MT
Dicerna Shares Soar on Takeover by Novo Nordisk	21-11-18	DJ
Wall Street Set for Positive Open as Upbeat Nvidia Earnings Buoy Sentiment	21-11-18	MT
Health Care Stocks Edge Higher Premarket Thursday	21-11-18	MT

Chart Dicerna Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. The Company's GalXC RNAi technology Platform consists of its liver-targeted GalXC technology and GalXC-Plus technology for tissues outside the liver. The Company's product line includes nedosiran, RG6346, belcesiran, and DCR-AUD. Its lead product candiadate nedosiran is a RNAi drug candidate developed for the treatment of hyperoxaluria (PH). The RG6346 for the treatment of chronic hepatitis B virus (HBV) infection. The belcesiran for the treatment of alpha-1 antitrypsin deficiency-associated liver disease (AATLD). The DCR-AUD for the treatment of alcohol use disorder (AUD).

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-3.10%	102B
REGENERON PHARMACEUTICALS, INC.	+2.11%	96.07B
ARGENX SE	-1.80%	21.66B
BIONTECH SE	-17.75%	20.77B
GENMAB A/S	-6.91%	18.53B
WUXI APPTEC CO., LTD.	-42.00%	16.91B
BEIGENE, LTD.	-28.19%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.18%	13.33B
SAREPTA THERAPEUTICS, INC.	+19.90%	10.94B

Bio Therapeutic Drugs